Dublin, Jan. 13, 2016 (GLOBE NEWSWIRE) -- Research and Markets (http://www.researchandmarkets.com/research/9tnsnk/u_s_glucose) has announced the addition of the "U.S. Glucose Testing Markets" report to their offering.
U.S. glucose testing is undergoing a significant transition, driven by new analytical technologies and developments in diabetes treatment. Although the blood glucose testing segment of the in vitro diagnostics (IVD) industry is mature, several segments of the market, such as home testing devices for diabetes management and point of care (POC) instruments for use in professional settings, will exhibit strong growth. Direct access testing has emerged as a strong force in the blood glucose testing segment, and non-invasive and minimally-invasive testing now represent major new areas for the application of IVD testing.
This report describes the specific market segments for blood glucose testing and diabetes management in the U.S. market. It reviews all of the generally-accepted clinical analytical methods that are currently in use today for measuring serum, plasma or whole-blood glucose concentrations. Additionally, this study examines clinical measurement devices, reagents and supplies as utilized in hospitals, clinics, doctor's offices and at-home care locations.
Moreover, it analyzes almost all of the companies known to be marketing, manufacturing or developing glucose testing products for the U.S. market. Each company is discussed in extensive depth with a section on its history, product line, business and marketing analysis, and a subjective commentary of the company's market position.
Key Topics Covered:
1. Overview
2. Diabetes
3. Market Analysis: Size, Growth, Share and Competitors
4. Glucose Diagnostic and Monitoring Recommendations
5. Glucose Testing Technology Platforms and Consumable Products
6. Glucose Testing Devices on the Market
7. Business Trends in Glucose Testing
8. Technology Trends
9. Company Profiles
Companies Mentioned
- Abaxis, Inc.
- Abbott Laboratories
- ACON Laboratories
- AgaMatrix
- Alere
- Allmedicus
- Amedica Biotech
- A. Menarini Diagnostics
- Apex Biotechnology Corporation
- Arkray
- Bayer
- B. Braun Melsungen
- Beckman Coulter
- Bionime
- Bio-Rad Laboratories, Inc.
- BioTex
- Calisto Medical
- Cambridge Sensors
- DexCom
- Diagnostic Devices/Prodigy Diabetes Care
- DiaSys
- Echo Therapeutics
- Entra Health Systems
- Fora Care
- Freedom Meditech
- Genesis Health Technologies
- GenExel-Sein
- GlucoPlus
- GluMetrics
- GlySens
- GlySure Limited
- Grove Instruments
For more information visit http://www.researchandmarkets.com/research/9tnsnk/u_s_glucose
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Glucose Testing


Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding?
TSMC Japan's Second Fab to Produce 3nm Chips by 2028
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage
Apple Turns 50: From Garage Startup to AI Crossroads
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push
First Western Ship Transits Strait of Hormuz Since Iran War Began
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 



